Literature DB >> 19101994

Potential chemotherapy side effects: what do oncologists tell parents?

Lisa Ysela Ramirez1, Samantha E Huestis, Tsiao Yi Yap, Stephen Zyzanski, Dennis Drotar, Eric Kodish.   

Abstract

BACKGROUND: In order to determine the number of short-term side effects and late effects discussed during an informed consent conference (ICC) after the diagnosis of acute leukemia, we observed the occurrence(s) and the ratio between short-term side effects versus late effects during an ICC. PROCEDURE: ICC(s) of childhood leukemia trials were audio-taped at six different study sites. The side effects mentioned during each of these ICC(s) were coded and analyzed.
RESULTS: One hundred forty cases were reviewed, from which we coded a total of 3,173 acute side effects and 242 late effects. The mean total side effects mentioned during each ICC was 24 (range 5-47). The number of late effects coded were significantly less than acute side effects. We also found that the duration of ICC(s) was positively correlated with the number of side effects mentioned. In addition, the frequency of total side effects mentioned was independent of patient or parent demographic factors.
CONCLUSIONS: Our results show that acute side effects are often mentioned but the discussion of late effects is much less frequent in the initial ICC(s). Careful consideration regarding the ratio of acute and late effects that are communicated to parents in the context of the ICC may facilitate parental understanding of clinically relevant side effects. Copyright 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19101994      PMCID: PMC2643320          DOI: 10.1002/pbc.21835

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  11 in total

1.  Stability of parental understanding of random assignment in childhood leukemia trials: an empirical examination of informed consent.

Authors:  Rachel Neff Greenley; Dennis Drotar; Stephen J Zyzanski; Eric Kodish
Journal:  J Clin Oncol       Date:  2006-02-20       Impact factor: 44.544

2.  How much information about adverse effects of medication do patients want from physicians?

Authors:  D K Ziegler; M C Mosier; M Buenaver; K Okuyemi
Journal:  Arch Intern Med       Date:  2001-03-12

3.  Parents' accounts of obtaining a diagnosis of childhood cancer.

Authors:  M Dixon-Woods; M Findlay; B Young; H Cox; D Heney
Journal:  Lancet       Date:  2001-03-03       Impact factor: 79.321

Review 4.  Informing and involving cancer patients in their own care.

Authors:  Michael Jefford; Martin H N Tattersall
Journal:  Lancet Oncol       Date:  2002-10       Impact factor: 41.316

5.  Doctor's views on disclosing or withholding information on low risks of complication.

Authors:  G G Palmboom; D L Willems; N B A T Janssen; J C J M de Haes
Journal:  J Med Ethics       Date:  2007-02       Impact factor: 2.903

6.  A survey of language barriers from the perspective of pediatric oncologists, interpreters, and parents.

Authors:  Marisa Abbe; Christian Simon; Anne Angiolillo; Kathy Ruccione; Eric D Kodish
Journal:  Pediatr Blood Cancer       Date:  2006-11       Impact factor: 3.167

Review 7.  Current concepts of communication skills training in oncology.

Authors:  L Fallowfield; V Jenkins
Journal:  Recent Results Cancer Res       Date:  2006

8.  Communication with parents of children with cancer.

Authors:  O B Eden; I Black; G A MacKinlay; A E Emery
Journal:  Palliat Med       Date:  1994       Impact factor: 4.762

9.  Giving information for a life-threatening diagnosis. Parents' and oncologists' perceptions.

Authors:  L W Greenberg; L S Jewett; R S Gluck; L A Champion; S L Leikin; M F Altieri; R N Lipnick
Journal:  Am J Dis Child       Date:  1984-07

10.  Communication of randomization in childhood leukemia trials.

Authors:  Eric Kodish; Michelle Eder; Robert B Noll; Kathleen Ruccione; Beverly Lange; Anne Angiolillo; Rebecca Pentz; Stephen Zyzanski; Laura A Siminoff; Dennis Drotar
Journal:  JAMA       Date:  2004-01-28       Impact factor: 56.272

View more
  29 in total

1.  Early information needs of adolescents and young adults about late effects of cancer treatment.

Authors:  Katie A Greenzang; Karen M Fasciano; Susan D Block; Jennifer W Mack
Journal:  Cancer       Date:  2020-05-04       Impact factor: 6.860

2.  The evolution of regret: decision-making for parents of children with cancer.

Authors:  Bryan A Sisk; Tammy I Kang; Jennifer W Mack
Journal:  Support Care Cancer       Date:  2019-06-20       Impact factor: 3.603

3.  The early addition of arsenic trioxide versus high-dose arabinoside is more effective and safe as consolidation chemotherapy for risk-tailored patients with acute promyelocytic leukemia: multicenter experience.

Authors:  Bin-Tao Huang; Qing-Chun Zeng; Arati Gurung; Wei-Hong Zhao; Zhen Xiao; Bing-Sheng Li
Journal:  Med Oncol       Date:  2011-10-30       Impact factor: 3.064

4.  High-dose homoharringtonine versus standard-dose daunorubicin is effective and safe as induction and post-induction chemotherapy for elderly patients with acute myeloid leukemia: a multicenter experience from China.

Authors:  Bin-Tao Huang; Qing-Chun Zeng; Jessica Yu; Xiao-Li Liu; Zhen Xiao; Hong-Qian Zhu
Journal:  Med Oncol       Date:  2011-01-22       Impact factor: 3.064

5.  Parental Considerations Regarding Cure and Late Effects for Children With Cancer.

Authors:  Katie A Greenzang; Hasan Al-Sayegh; Clement Ma; Mehdi Najafzadeh; Eve Wittenberg; Jennifer W Mack
Journal:  Pediatrics       Date:  2020-04-13       Impact factor: 7.124

6.  Parental distress and desire for information regarding long-term implications of pediatric cancer treatment.

Authors:  Katie A Greenzang; Angel M Cronin; Tammy I Kang; Jennifer W Mack
Journal:  Cancer       Date:  2018-10-01       Impact factor: 6.860

7.  Advancing the field of communication research in pediatric oncology: A systematic review of the literature analyzing medical dialogue.

Authors:  Erica C Kaye; Ashley Kiefer; Kristina Zalud; Melanie Gattas; Ian Snyder; Holly Spraker-Perlman; Justin N Baker
Journal:  Pediatr Blood Cancer       Date:  2018-08-01       Impact factor: 3.167

8.  A prospective, observational study of added medium-dose cytosine arabinoside versus As2O3 for elderly patients with acute promyelocytic leukemia.

Authors:  Bin-Tao Huang; Qing-Chun Zeng; Wei-Hong Zhao; Bing-Sheng Li; Rui-lin Chen
Journal:  Med Oncol       Date:  2014-09-12       Impact factor: 3.064

9.  Parent understanding of the risk of future limitations secondary to pediatric cancer treatment.

Authors:  Katie A Greenzang; Angel M Cronin; Tammy Kang; Jennifer W Mack
Journal:  Pediatr Blood Cancer       Date:  2018-03-30       Impact factor: 3.167

Review 10.  Potential therapeutic applications of plant toxin-ricin in cancer: challenges and advances.

Authors:  Nikhil Tyagi; Monika Tyagi; Manendra Pachauri; Prahlad C Ghosh
Journal:  Tumour Biol       Date:  2015-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.